IP Library › Granted Patent US 11,920,159
Granted Patent B2
US 11,920,159 · App. 16/620,839 · Granted Mar 5, 2024

Methods for expanding hematopoietic stem cells using revitalized mesenchymal stem cells

Inventors: Paul S. Frenette (New York, NY); Fumio Nakahara (Bronx, NY)
Assignee: ALBERT EINSTEIN COLLEGE OF MEDICINE
C12N5/0663A61K35/28C12N15/86C12N2506/11C12N2506/30C12N2740/15043
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,920,159
App. No.
16/620,839
Granted
Mar 5, 2024
Kind
B2
Abstract

A method for revitalizing mesenchymal stem cells (MSC) maintained in culture by transducing the MSC with vectors encoding a specific gene combination, as well as methods of use of MSC so revitalized in co-culturing hematopoietic stem cells.

Claims (3)

1. A modified mesenchymal stem cell (MSC) comprising a mesenchymal stem cell (MSC) modified to express the genes Ostf1 (osteoclast stimulating factor 1), Xbp1 (X-box binding protein 1), Irf3 (interferon regulatory factor 3), and Irf7 (interferon regulatory factor 7), wherein the MSC is modified by transduction with one or more vector(s) encoding the genes Ostf1, Xbp1, Irf3, and Irf7, and wherein the modified MSC is a revitalized MSC.

2. The composition of claim 1 , wherein the MSC is further modified to express the Klf7 (Kruppel-like factor 7) gene.

3. The composition of claim 2 , wherein the mesenchymal stem cell (MSC) is modified by transduction to express the Klf7 gene.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 24, 2020
From: FRENETTE, PAUL S.; NAKAHARA, FUMIO
To: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Reel/Frame 051617/0969 →
MERGER Recorded Jan 24, 2020
From: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
To: ALBERT EINSTEIN COLLEGE OF MEDICINE
Reel/Frame 051696/0337 →